🔒 Why Is This Section Restricted?

The full content is restricted due to the high strategic value of the positioning data it contains. Specifically:

• It presents a logic of therapeutic substitution, positioning PLPC-DB as the sole viable immunological alternative in patient populations that have been systematically excluded from all current immunotherapies. Public access could be misinterpreted as overreach or used by competitors to reshape their own off-label arguments.
• It identifies immune phenotypes (e.g., IL-10↑, CD69⁻, HLA-DR↓) that justify PLPC-DB deployment without conventional indications. This logic is central to the platform’s non-receptor-based mechanism, and exposing it undermines proprietary differentiation.
• It includes a clinical value statement explaining why PLPC-DB can be used without systemic lymphocyte functionality—dismantling the core assumptions of current IO therapies (CAR-T, ICIs, TILs). This framework is highly sensitive from a regulatory and licensing standpoint.
• It supports clinical–tumoral dissociation models, documenting that therapeutic success can be functional and immunological even in the absence of tumor regression. Publicizing this alters standard oncology evaluation frameworks.
• It includes graphical stratification of patient populations, indicating suitability zones. This segmentation matrix is part of the licensing argumentation for regional application, and must remain controlled during negotiation phases.

In short, this page reveals not just who can benefit—but why no one else can serve them. That is proprietary clinical territory.